Manufacturing AsymBio to secure $184m to support growth in biologics manufacturing Pharmaceutical Business ReviewThe funds will be used for AsymBio's principal business operations and drive further expansion of its manufacturing capacity.Read full story pharminent August 5, 2026 (Last updated: August 5, 2026) Pharmaceutical Business Review The funds will be used for AsymBio’s principal business operations and drive further expansion of its manufacturing capacity. Read full story Post navigation Previous: Pfizer Axes Ex-Metsera Obesity Asset and GIPR Prospect in Quarterly Pipeline ClearoutNext: Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 Related Stories Manufacturing Samsung Biologics inks $262M manufacturing deal with European pharma company pharminent September 11, 2026 Manufacturing Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision pharminent September 9, 2026 Manufacturing US puts $125m into personalised RNA therapy production pharminent September 2, 2026